title: Telomere length shortening of peripheral blood mononuclear cells in solid-cancer patients undergoing standard-dose chemotherapy might be correlated with good treatment response and neutropenia severity.
abstract: This study evaluated the telomere length changes (DeltaTL) of peripheral blood mononuclear cells before and after repetitive standard-dose nonmyeloablative chemotherapy and the association of DeltaTL with treatment response and myelosuppression severity. TL was measured with Southern blot analysis in 32 solid-cancer patients without bone marrow metastasis. The mean TL before chemotherapy (t0 TL) and after the 2nd (t1 TL), 4th (t2 TL) and 6th cycle (t3 TL) was 8.49, 8.33, 8.08 and 8.10 kb, respectively. TL became significantly decreased after 4 (p = 0.005) and 6 (p = 0.026) cycles of chemotherapy. The mean value of DeltaTL before and after completion of chemotherapy (t0 TL - t3 TL) was 0.46 kb. DeltaTL has a significant correlation with good treatment response (r = 0.448, p = 0.005) and the frequency of severe neutropenia (r = 0.417, p < 0.05). Consequently, TL of peripheral blood mononuclear cells was decreased by the repetitive nonmyeloablative standard-dose chemotherapy in solid-cancer patients without bone marrow metastasis, and DeltaTL was associated with good treatment response and neutropenia severity.
authors.affiliation: Department of Internal Medicine, Konkuk University Hospital, Seoul, Korea.
authors.forename: So Young
authors.initials: SY
authors.lastname: Yoon
authors.forename: Hwa Jung
authors.initials: HJ
authors.lastname: Sung
authors.forename: Kyong Hwa
authors.initials: KH
authors.lastname: Park
authors.forename: In Keun
authors.initials: IK
authors.lastname: Choi
authors.forename: Seok Jin
authors.initials: SJ
authors.lastname: Kim
authors.forename: Sang Cheul
authors.initials: SC
authors.lastname: Oh
authors.forename: Jae Hong
authors.initials: JH
authors.lastname: Seo
authors.forename: Chul Won
authors.initials: CW
authors.lastname: Choi
authors.forename: Byung Soo
authors.initials: BS
authors.lastname: Kim
authors.forename: Sang Won
authors.initials: SW
authors.lastname: Shin
authors.forename: Yeul Hong
authors.initials: YH
authors.lastname: Kim
authors.forename: Jun Suk
authors.initials: JS
authors.lastname: Kim
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D014408:Biomarkers, Tumor / Q000097:blood; D015331:Cohort Studies; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology* / Q000401:mortality; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology*; D011336:Probability; D011446:Prospective Studies; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D019098:Telomerase / Q000378:metabolism*; D016615:Telomere / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D019098:Telomerase